Clinical trials: Advanced Solid Tumors Patients
Breast Cancer, Solid Tumor
A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
This study is an open, multicenter, increasing dose and dose extension nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics and preliminary efficacy of BL-B16D1 in patients…
- Trial name
- NCT06493864
- Testing
- BL-B16D1
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Solid Tumors, Neuroendocrine Tumors
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
To select RP2D/MTD of HBM4003 in combination with Toripalimab in dose confirmation part(Part 1) and use the RP2D in dose expansion part (Part 2) to evaluate the safety, tolerability, PK/PD and preliminary efficacy of in patients…
- Conditions
- Solid Tumors, Neuroendocrine Tumors, CRC
- Trial name
- NCT05167071
- Testing
- HBM4003, Toripalimab, Tislelizumab
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Advanced Solid Tumors
A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.
- Trial name
- NCT00708006
- Testing
- HGS1029
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Human Genome Sciences Inc.
Advanced Malignant Solid Tumor
Phase I/II Study of SCTB39G in Advanced Solid Tumours
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39G as a monotherapy in adult patients with advanced malignant solid tumours.
- Trial name
- NCT07077252
- Testing
- SCTB39G
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sinocelltech Ltd.
Advanced Solid Tumor Cancer
A Study to Evaluate YF087 in Subjects With MSI-H or dMMR Advanced Solid Tumors
This is an open-label, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of YF087 in subjects with Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) advanced solid…
- Trial name
- NCT07809607
- Testing
- YF087
- Volunteers
- 70 people
- Sponsor
- InventisBio Co., Ltd
Locally Advanced or Metastatic Solid Tumors
Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors
This is a phase I study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC3195 in Patients with Locally Advanced or Metastatic Solid Tumors.
- Trial name
- BC3195 (NCT05957471)
- Testing
- Drug: BC3195 for Injection
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
Solid Tumors
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
The main aim of this study is to assess how the human body of adults with advanced or metastatic solid tumors absorbs, distributes, metabolizes and excretes subasumstat following a single 1 hour infusion of subasumstat.
- Trial name
- NCT05976334
- Testing
- [14C] Subasumstat, Subasumstat
- Where
- 2 sites in Hungary
- Volunteers
- 3 people
- Sponsor
- Takeda
Advanced Solid Tumors
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
This is a first in human, open-label, sequential dose escalation and expansion study of AMG 780 in up to 62 subjects with advanced solid tumors.
- Trial name
- NCT01137552
- Testing
- AMG 780
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Amgen
Advanced Neoplastic Disease
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors
Primary Objective: To determine the dose limiting toxicity (DLT), the maximum administered dose (MAD) and the maximum tolerated dose (MTD) of AVE8062 and docetaxel in combination administered sequentially on D1 \& D2 respectively…
- Trial name
- NCT01907685
- Testing
- AVE8062, Docetaxel
- Volunteers
- 58 people
- Sponsor
- Sanofi
Cancer, Solid Tumors
Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055
The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.
- Conditions
- Cancer, Solid Tumors, Advanced Solid Malignancies
- Trial name
- NCT00973076
- Testing
- AZD8055
- Where
- Japan
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Cancer, Solid Tumor Cancer
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies.
- Conditions
- Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate
- Trial name
- NCT07424547
- Testing
- SYS6043
- Where
- 5 sites in United States
- Volunteers
- 386 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1.
- Trial name
- NCT03733990
- Testing
- FP-1305 (bexmarilimab)
- Where
- 11 sites in United States, Finland and 4 more
- Volunteers
- 216 people
- Sponsor
- Faron Pharmaceuticals Ltd
Solid Tumors
A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
This is an open-label, multicenter, dose-escalation and expansion Phase Ib clinical study of RO6958688 in combination with atezolizumab. Part I of the study is subdivided into parts IA and IB.
- Trial name
- NCT02650713
- Testing
- Atezolizumab, RO6958688
- Where
- 24 sites in United States, Canada and 5 more
- Volunteers
- 228 people
- Sponsor
- Hoffmann-La Roche
Advanced Malignancies
A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors
TQB6426 is a glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Trial name
- NCT07730190
- Testing
- TQB6426 for Injection
- Where
- 8 sites in China
- Volunteers
- 145 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Breast Cancer, Colorectal Cancer
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
This is a Phase 2, open-label, multicenter study whose principal objectives are to evaluate the efficacy and safety/tolerability of poziotinib in five cohorts of 30 previously-treated patients each.
- Conditions
- Breast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme
- Trial name
- NCT04172597
- Testing
- Poziotinib Hydrochloride, Loperamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Advanced/Metastatic Solid Tumors, NSCLC
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX37 in patients with advanced/metastatic solid tumors.
- Trial name
- NCT07274813
- Testing
- HLX37
- Where
- 2 sites in China
- Volunteers
- 254 people
- Sponsor
- Shanghai Henlius Biotech
Cancer
A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors
The primary purpose of this study is to evaluate the effect of food on oral LBH589 in adult patients with advanced solid tumors.
- Trial name
- NCT00570284
- Testing
- LBH589
- Where
- 9 sites in United States, Sweden and 1 more
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Lung Cancer
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors
- Conditions
- Melanoma, Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03050047
- Testing
- BCD-100
- Where
- 4 sites in Russia
- Volunteers
- 15 people
- Sponsor
- Biocad
Neoplasms
A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread
The primary objective of this trial is to determine the maximum tolerated dose (MTD)/optimal biological dose (OBD) of BI 905681 given as an intravenous infusion and to determine the recommended dose and dosing schedule for…
- Trial name
- NCT04147247
- Testing
- BI 905681
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.